Top

Published in:

Open Access 01-10-2020 | Colon Cancer | Original Article

The effects of tumor resection and adjuvant therapy on the peripheral blood immune cell profile in patients with colon carcinoma

Authors: Daniëlle Krijgsman, Natasja L. De Vries, Morten N. Andersen, Anni Skovbo, Rob A. E. M. Tollenaar, Esther Bastiaannet, Peter J. K. Kuppen, Marianne Hokland

Published in: Cancer Immunology, Immunotherapy | Issue 10/2020

Abstract

Objective

The subset distribution and immunophenotype of circulating immune cells (“peripheral blood immune cell profile”) may reflect tumor development and response to cancer treatment. In order to use the peripheral blood immune cell profile as biomarker to monitor patients over time, it is crucial to know how immune cell subsets respond to therapeutic interventions. In this study, we investigated the effects of tumor resection and adjuvant therapy on the peripheral blood immune cell profile in patients with colon carcinoma (CC).

Methods

The subset distribution and immunophenotype of T cells (CD3⁺CD56⁻), CD56^dim NK cells (CD3⁻CD56^dim), CD56^bright NK cells (CD3⁻CD56^bright) and NKT-like cells (CD3⁺CD56⁺) were studied in preoperative and postoperative peripheral blood mononuclear cell (PBMC) samples of 24 patients with CC by multiparameter flow cytometry. Changes in immunophenotype of circulating immune cells after tumor resection were studied in patients treated with and without (capecitabine-based) adjuvant therapy.

Results

The NKT-like cell (% of total PBMCs) and CD8⁺ T cell (% of total T cells) populations expanded in the peripheral blood of non-adjuvant-treated CC patients after surgery. NK- and NKT-like cells showed upregulation of activating receptors and downregulation of inhibitory receptors in non-adjuvant-treated CC patients after surgery. These changes were not observed in the peripheral blood of adjuvant-treated CC patients.

Conclusions

Our results suggest tumor-induced suppression of NK- and NKT-like cells in CC patients, an effect that could not be detected after tumor resection. In contrast, adjuvant therapy maintained tumor-induced immunosuppression of NK- and NKT-like cells in CC patients.

Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781. https://doi.org/10.1016/j.ejca.2009.12.014CrossRefPubMed

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. https://doi.org/10.1016/j.ejca.2012.12.027CrossRefPubMed

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–386. https://doi.org/10.1002/ijc.29210CrossRefPubMed

van Cutsem E, Cervantes A, Nordlinger B, Arnold D, ESMO Guidelines Working Group (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Suppl 3:1–9

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964. https://doi.org/10.1126/science.1129139CrossRefPubMed

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29(6):610–618. https://doi.org/10.1200/JCO.2010.30.5425CrossRefPubMed

Finn OJ (2012) Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance. Exp Mol Pathol 93(3):315–318. https://doi.org/10.1016/j.yexmp.2012.10.013CrossRefPubMedPubMedCentral

Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pages F (2014) Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 232(2):199–209. https://doi.org/10.1002/path.4287CrossRefPubMed

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Kirilovsky A, Obenauf AC, Hamieh M, Berger A, Bruneval P, Tuech JJ, Sabourin JC, Le Pessot F, Mauillon J, Rafii A, Laurent-Puig P, Speicher MR, Trajanoski Z, Michel P, Sesboue R, Frebourg T, Pages F, Valge-Archer V, Latouche JB, Galon J (2016) Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44(3):698–711. https://doi.org/10.1016/j.immuni.2016.02.025CrossRefPubMed

10.

Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Pagès F (2014) Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 232(2):199–209CrossRefPubMed

11.

Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Borger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grutzmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Leonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Musina AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J (2018) International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391 (10135):2128–2139. https://doi.org/10.1016/S0140-6736(18)30789-X

12.

Krijgsman D, de Vries NL, Skovbo A, Andersen MN, Swets M, Bastiaannet E, Vahrmeijer AL, van de Velde CJH, Heemskerk MHM, Hokland M, Kuppen PJK (2019) Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile. Cancer Immunol Immunother. https://doi.org/10.1007/s00262-019-02343-7CrossRefPubMedPubMedCentral

13.

Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633–640CrossRefPubMed

14.

Jonges LE, Albertsson P, van Vlierberghe RL, Ensink NG, Johansson BR, van de Velde CJ, Fleuren GJ, Nannmark U, Kuppen PJ (2001) The phenotypic heterogeneity of human natural killer cells: presence of at least 48 different subsets in the peripheral blood. Scand J Immunol 53(2):103–110CrossRefPubMed

15.

Krijgsman D, Hokland M, Kuppen PJK (2018) The role of natural killer T cells in cancer-a phenotypical and functional approach. Front Immunol 9:367. https://doi.org/10.3389/fimmu.2018.00367CrossRefPubMedPubMedCentral

16.

Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M et al (2001) Human natural killer cell receptors and co-receptors. Immunol Rev 181:203–214CrossRefPubMed

17.

Dutertre CA, Bonnin-Gelize E, Pulford K, Bourel D, Fridman WH, Teillaud JL (2008) A novel subset of NK cells expressing high levels of inhibitory FcgammaRIIB modulating antibody-dependent function. J Leukoc Biol 84(6):1511–1520. https://doi.org/10.1189/jlb.0608343CrossRefPubMed

18.

Addison EG, North J, Bakhsh I, Marden C, Haq S, Al-Sarraj S, Malayeri R, Wickremasinghe RG, Davies JK, Lowdell MW (2005) Ligation of CD8alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity. Immunology 116(3):354–361. https://doi.org/10.1111/j.1365-2567.2005.02235.xCrossRefPubMedPubMedCentral

19.

Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC et al (2013) Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med 11:262. https://doi.org/10.1186/1479-5876-11-262CrossRefPubMedPubMedCentral

20.

Rocca YS, Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB et al (2013) Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun 19(1):76–85. https://doi.org/10.1177/1753425912453187CrossRefPubMed

21.

Gharagozloo M, Rezaei A, Kalantari H, Bahador A, Hassannejad N, Maracy M, Nouri N, Sedghi M, Ghazanfari H, Bayat B (2018) Decline in peripheral blood NKG2D+CD3+CD56+ NKT cells in metastatic colorectal cancer patients. Bratisl Lek Listy 119(1):6–11. https://doi.org/10.4149/BLL_2018_002CrossRefPubMed

22.

Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E, Janji B (2013) The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol 4:490. https://doi.org/10.3389/fimmu.2013.00490CrossRefPubMedPubMedCentral

23.

Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L (2014) Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol 44(6):1582–1592. https://doi.org/10.1002/eji.201344272CrossRefPubMed

24.

Balsamo M, Manzini C, Pietra G, Raggi F, Blengio F, Mingari MC, Varesio L, Moretta L, Bosco MC, Vitale M (2013) Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. Eur J Immunol 43(10):2756–2764. https://doi.org/10.1002/eji.201343448CrossRefPubMed

25.

Han B, Mao FY, Zhao YL, Lv YP, Teng YS, Duan M, Chen W, Cheng P, Wang TT, Liang ZY, Zhang JY, Liu YG, Guo G, Zou QM, Zhuang Y, Peng LS (2018) Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer. J Immunol Res 2018:6248590. https://doi.org/10.1155/2018/6248590CrossRefPubMedPubMedCentral

26.

Valayer A, Brea D, Lajoie L, Avezard L, Combes-Soia L, Labas V, Korkmaz B, Thibault G, Baranek T, Si-Tahar M (2017) Neutrophils can disarm NK cell response through cleavage of NKp46. J Leukoc Biol 101(1):253–259. https://doi.org/10.1189/jlb.3AB0316-140RRCrossRefPubMed

27.

Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21(1):15–25. https://doi.org/10.1038/cdd.2013.67CrossRefPubMed

28.

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 57(1):289–300

29.

Lynch HT, Drescher KM, de la Chapelle A (2008) Immunology and the Lynch syndrome. Gastroenterology 134(4):1246–1249. https://doi.org/10.1053/j.gastro.2008.02.008CrossRefPubMed

30.

Klatka J, Grywalska E, Hymos A, Krasowska E, Mielnik M, Siwicka-Gieroba D, Markowicz J, Trojanowski P, Olszanski W, Rolinski J (2017) Subpopulations of natural killer-T-like cells before and after surgical treatment of laryngeal cancer. Cent Eur J Immunol 42(3):252–258. https://doi.org/10.5114/ceji.2017.70967CrossRefPubMedPubMedCentral

31.

Grimm M, Feyen O, Hofmann H, Teriete P, Biegner T, Munz A, Reinert S (2016) Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. Tumour Biol 37(3):3807–3816. https://doi.org/10.1007/s13277-015-4224-2CrossRefPubMed

32.

Angka L, Martel AB, Kilgour M, Jeong A, Sadiq M, de Souza CT, Baker L, Kennedy MA, Kekre N, Auer RC (2018) Natural killer cell IFNgamma secretion is profoundly suppressed following colorectal cancer surgery. Ann Surg Oncol 25(12):3747–3754. https://doi.org/10.1245/s10434-018-6691-3CrossRefPubMed

33.

Molling JW, Kolgen W, van der Vliet HJ, Boomsma MF, Kruizenga H, Smorenburg CH, Molenkamp BG, Langendijk JA, Leemans CR, von Blomberg BM, Scheper RJ, van den Eertwegh AJ (2005) Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116(1):87–93. https://doi.org/10.1002/ijc.20998CrossRefPubMed

34.

Dovsak T, Ihan A, Didanovic V, Kansky A, Verdenik M, Hren NI (2018) Effect of surgery and radiotherapy on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced oral cancer. BMC Cancer 18(1):235. https://doi.org/10.1186/s12885-018-4136-9CrossRefPubMedPubMedCentral

35.

Wang WH, Xu HY, Zhao ZM, Zhang GM, Lin FW (2018) Dynamic and significant changes of T-cell subgroups in breast cancer patients during surgery and chemotherapy. Int Immunopharmacol 65:279–283. https://doi.org/10.1016/j.intimp.2018.09.039CrossRefPubMed

36.

Lachmann G, von Haefen C, Kurth J, Yuerek F, Spies C (2018) Innate immunity recovers earlier than acquired immunity during severe postoperative immunosuppression. Int J Med Sci 15(1):1–9. https://doi.org/10.7150/ijms.21433CrossRefPubMedPubMedCentral

37.

Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CR (2016) Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res 18(1):10. https://doi.org/10.1186/s13058-015-0669-xCrossRefPubMedPubMedCentral

Title: The effects of tumor resection and adjuvant therapy on the peripheral blood immune cell profile in patients with colon carcinoma
Authors: Daniëlle Krijgsman
Natasja L. De Vries
Morten N. Andersen
Anni Skovbo
Rob A. E. M. Tollenaar
Esther Bastiaannet
Peter J. K. Kuppen
Marianne Hokland
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keywords: Colon Cancer
Colon Cancer
Published in: Cancer Immunology, Immunotherapy / Issue 10/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02590-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2020

Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model

Observations on neuroimmunomodulation as a novel therapeutic strategy in metastasis

Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer

Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion

Are we ready to use TMB in breast cancer clinical practice?

Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer